David Steensma, MD
@davidsteensma
Hematologist-oncologist. @AjaxThx CMO. Former Edward P. Evans Chair in MDS @DanaFarber, @HarvardMed & @MayoClinic faculty, @NovartisScience hematology head.
ID: 2739065578
10-08-2014 14:36:07
7,7K Tweet
25,25K Takipçi
460 Takip Edilen
I remember a long-ago FDA Oncology meeting with a small company developing an MDS drug. The company was convinced their drug was synergistic with HMAs & kept saying “we’re 2+2=5.” Finally an FDA official said they were perfectly happy for 2+2 to equal 4, if 4 was safe patients.